Correlations between plasma endothelin-1 levels and breakthrough pain in patients with cancer.
Correlations between plasma endothelin-1 levels and breakthrough pain in patients with cancer.
复制标题
癌症患者血浆内皮素-1 水平与爆发性疼痛之间的相关性。
DOI：
10.2147/ott.s90272
复制
发表时间：
2015
影响因子：
4
通讯作者：
Huang D
中科院分区：
文献类型：
--
作者：
Yan XB;Peng TC;Huang D
内皮素-1 （ET-1）可能参与晚期癌症患者的疼痛驱动。然而，很少有研究关注ET-1在突破性疼痛（BP）中的作用。这项关键研究的目的是探讨血浆（ET-1）水平与血压强度之间的关系。共纳入40例患者，分为两组：BP组和非BP组。另取20名健康成人作为正常对照组。疼痛强度采用视觉模拟量表（VAS）评分1-10分。血浆ET-1水平用ET放射免疫测定试剂盒检测。随后，采用Pearson相关系数分析ET-1水平与VAS评分及肿瘤类型的相关性。高血压组血浆ET-1水平（35.31±8.02 pg/mL）高于非高血压组（29.51±6.78 pg/mL）和正常对照组（24.77±10.10 pg/mL， P<0.05）。血压组VAS评分（7.45±0.82）高于非血压组（2.80±1.23，P<0.05）。血浆ET-1水平与BP组VAS评分呈正相关（Pearson’s r=0.42）。非bp组患者血浆ET-1水平与VAS评分（Pearson’s r= - 0.22）、肿瘤类型（P < 0.05）无显著相关性。血浆ET-1水平升高与BP呈正相关，靶向ET-1可能为BP提供一种新的镇痛治疗方法。
Endothelin-1 (ET-1) may be involved in driving pain in patients with advanced cancer. However, a few studies focus on the role of ET-1 in breakthrough pain (BP). The aim of this pivotal study was to explore the correlation between the plasma (ET-1) level and BP intensity. A total of 40 patients were enrolled in the study, and they were divided into two groups: BP group and non-BP group. Moreover, 20 healthy adults were used as the normal control group. Pain intensity was measured using visual analog scale (VAS) scores of 1–10. Plasma ET-1 levels were detected by an ET radioimmunoassay kit. Subsequently, the correlation of ET-1 level with the VAS score and cancer types was analyzed by Pearson’s correlation coefficient. The plasma ET-1 level in the BP group (35.31±8.02 pg/mL) was higher than that in the non-BP group (29.51±6.78 pg/mL) and the normal control group (24.77±10.10 pg/mL, P<0.05). In addition, the VAS score in the BP group (7.45±0.82) was higher than that in the non-BP group (2.80±1.23, P<0.05). The plasma ET-1 level was positively correlated with the VAS score of the BP group (Pearson’s r=0.42). There was no significant correlation between the plasma ET-1 level and VAS score of the non-BP group (Pearson’s r=−0.22) or/and cancer types (P>0.05). The elevated plasma ET-1 levels were positively related to BP, and targeting ET-1 may provide a novel pain-reducing therapeutic treatment in BP.